United States · Platforms & data · TipRanks

PegBio’s Paidakang Included in China’s 2026 NRDL

Published by TipRanks · United States 10 h ago

Detailed summary

PegBio Co., Ltd. Class H ( ($HK:2565) ) has issued an announcement. PegBio is an innovative-drug developer focused on metabolic diseases; its first marketed ...

Read the full article on TipRanks Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.tipranks.com)

Also worth reading

The Motley Fool

What To Expect In Markets This Week: NVDA, PANW, DIS, HD, TGT, WMT, GRRR Earnings, Kevin Warsh Speech And More

Seeking Alpha

PegBio’s Paidakang Included in China’s 2026 NRDL

Detailed summary

Share

Also worth reading

Prediction: Rigetti Computing Stock Will Be Worth This Much in 1 Year

German American Bancorp director Bawel buys $19,999 in shares

Bitcoin Faces Final Capitulation Risk: Could $40,000 Be Next?

Nvidia earnings collide with Fed’s biggest AI challenge under Warsh

What To Expect In Markets This Week: NVDA, PANW, DIS, HD, TGT, WMT, GRRR Earnings, Kevin Warsh Speech And More

Global oil market moves to surplus as Persian Gulf shipments rebound, IEA says